1 – 10 of 77
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Longitudinal Tau PET Using 18F-Flortaucipir : The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters
2023) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 64(2). p.281-286(
- Contribution to journal › Article
- 2022
-
Mark
Dosimetric quantities of neuroendocrine tumors over treatment cycles with 177Lu-DOTA-TATE
(
- Contribution to journal › Article
-
Mark
Alzheimer Disease : Standard of Diagnosis, Treatment, Care, and Prevention
(
- Contribution to journal › Article
-
Mark
Tau PET Imaging in Neurodegenerative Disorders
2022) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 63. p.20-26(
- Contribution to journal › Article
- 2021
-
Mark
Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer
2021) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 62(7). p.989-995(
- Contribution to journal › Article
-
Mark
Improved 223Ra Therapy with Combination Epithelial Sodium Channel Blockade
(
- Contribution to journal › Article
- 2020
-
Mark
Denoising of Scintillation Camera Images Using a Deep Convolutional Neural Network : A Monte Carlo Simulation Approach
(
- Contribution to journal › Article
-
Mark
Assessing Radiographic Response to 223Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients
(
- Contribution to journal › Article
- 2019
-
Mark
Recombinant alpha-1-microglobulin is a potential kidney protector in 177Lu-octreotate treatment of neuroendocrine tumors
(
- Contribution to journal › Article
-
Mark
Preserving Preclinical PET Quality During Intratherapeutic Imaging in Radionuclide Therapy with Rose Metal Shielding Reducing Photon Flux
(
- Contribution to journal › Article